Travere Therapeutics Inc (NASDAQ:TVTX)
| 8.05 Delayed Data As of 3:59pm ET |  +0.195 / +2.48%Today’s Change | 7.00 Today|||52-Week Range 26.55 | -61.75% Year-to-Date |
Latest TVTX News | Press Releases
| Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study Sep 22 / Zacks.com - Paid Partner Content | Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last? Sep 18 / Zacks.com - Paid Partner Content |
| Why Shares of Travere Therapeutics Are Slumping Thursday Sep 21 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 7.85 |
| Today’s open | 7.76 |
| Day’s range | 7.55 - 8.06 |
| Volume | 121,211 |
| Average volume (3 months) | 1,341,174 |
| Market cap | $590.3M |
Data as of 3:59pm ET, 09/25/2023
Growth & Valuation
| Earnings growth (last year) | -45.11% |
| Earnings growth (this year) | +4.12% |
| Earnings growth (next 5 years) | +37.50% |
| Revenue growth (last year) | -6.80% |
| P/E ratio | NM |
| Price/Sales | 6.32 |
| Price/Book | 11.81 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| RAPTRapt Therapeutics In... | -0.10 | -0.58% |
| CDMOAvid Bioservices Inc | +0.09 | +0.94% |
| ALECAlector Inc | +0.09 | +1.38% |
| ALLOAllogene Therapeutic... | -0.17 | -4.51% |
Data as of 3:59pm ET, 09/25/2023
Financials
| Next reporting date | November 2, 2023 |
| EPS forecast (this quarter) | -$1.02 |
| Annual revenue (last year) | $212.0M |
| Annual profit (last year) | -$278.5M |
| Net profit margin | -131.35% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
